首页 产业/市场分类 出版商一览 Email 通知 GII媒体代理会议 公司简介 联络我们
- English Japanese Korean
首页 > 市场调查报告书 > 制药 > 处方药 > Talactoferrin Alfa(NSCLC):到2020年为止的分析与预测
产业/市场分类
制药 (4823)
肥胖症治疗 (44)
非专利药 (129)
疫苗 (181)
神经疾病 (172)
骨头疾病治疗 (37)
动物用医药 (18)
处方药 (156)
规章 (130)
感染疾病 (347)
精神病 (85)
制药企业 (526)
糖尿病 (191)
癌症 (903)
药物开发 (1458)
DDS (182)
OTC 非处方药 (150)
市场调查报告书

Talactoferrin Alfa(NSCLC):到2020年为止的分析与预测

Talactoferrin Alfa (NSCLC) - Analysis and Forecasts to 2020

出版商 GlobalData
出版日期 2011年10月 商品编码 222279
内容信息 英文 Pages: 35
价格
US $ 2000 PDF by E-mail (Single user license)
US $ 4000 PDF by E-mail (Site license)
US $ 6000 PDF by E-mail (Global license)


Talactoferrin Alfa(NSCLC):到2020年为止的分析与预测 是由出版商GlobalData在2011年10月所出版的。 这份英文市场调查报告书包含Pages: 35 价格从美金2000起跳。

简介

全球非小细胞肺癌(NSCLC)市场在2009年达到40亿美金的规模，一般认为到2020年将会达到70忆美金。不但有Avastin及Alimta等领导市场，更有Afatinib、Erbitux、Stimuvax等有潜力开发平台药物维持市场的成长。Talactoferrin Alfa为Agennix AG的产品，多被研发于许多癌症及严重败血症治疗上的口服生技药物上。

本报告提供全球非小细胞肺癌(NSCLC)市场概要与市场特性，TNM分类，以及Talactoferrin Alfa的概要与作用机制，临床实验趋势，销售额预测汇整，为您概述为以下内容。

第1章 目录

第2章 简介

  • NSCLC市场
  • 免疫学
  • 病因
    • 抽烟
    • 放射线
    • 石棉
    • 大气污染
    • 其他环境因素
  • 报告指南

第3章 NSCLC:市场特性

  • NSCLC疾病市场
  • 市场预测和年复合成长率
  • 推动市场的要素
    • 高发病率
    • 高死亡率
    • 早期NSCLC的化疗的使用扩大
    • 标靶药物和维护疗法的上市
    • 有前途的开发平台药物

第4章 TNM分类

第5章 Talactoferrin Alfa

  • 简介
  • 作用机制
  • 临床实验
  • 影响Talactoferrin Alfa销售额的因素
    • Fast Track Designation
    • 高效性
    • 低毒性简介
    • 大规模的患者群
    • 施打方式的便利性
  • 药物评估
    • 药物风险·优点评分
    • 竞争度
  • 销售额预测
    • 目标患者群
    • 用量决策
    • 市场渗透度
    • 年度治疗费用
    • 销售额预测

第6章 附录

图表

目录

Abstract

Summary

GlobalData's pharmaceuticals report, "Talactoferrin Alfa (NSCLC) - Analysis and Forecasts to 2020" provides Talactoferrin Alfa sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Talactoferrin Alfa including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Talactoferrin Alfa including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2002-2020 for Talactoferrin Alfa in the US, EU-5, Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of contents

1 Table of contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Introduction 4

  • 2.1 NSCLC Market 4
  • 2.2 Epidemiology 4
  • 2.3 Etiology 6
    • 2.3.1 Tobacco 6
    • 2.3.2 Radiation 7
    • 2.3.3 Asbestos 8
    • 2.3.4 Air pollution 8
    • 2.3.5 Other Environmental Agents 8
  • 2.4 GlobalData Pipeline Report Guidance 9

3 NSCLC Disease: Market Characterization 10

  • 3.1 NSCLC Disease Market 10
  • 3.2 NSCLC Disease Market Forecasts and CAGR 10
  • 3.3 Drivers for the NSCLC Disease Market 10
    • 3.3.1 High Incidence 11
    • 3.3.2 High Mortality Rate 12
    • 3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 12
    • 3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 12
    • 3.3.5 Promising Pipeline Drugs 12

4 Tumor-Node-Metastases (TNM) Classification of NSCLC 13

5 Talactoferrin Alfa 17

  • 5.1 Introduction 17
  • 5.2 Mechanism of Action 17
  • 5.3 Clinical Studies 17
  • 5.4 Factors Affecting Sales of Talactoferrin Alfa 18
    • 5.4.1 Fast Track Designation 18
    • 5.4.2 High Efficacy 18
    • 5.4.3 Low Toxicity Profile 18
    • 5.4.4 Larger Patient Pool 19
    • 5.4.5 Convenient Administration 19
  • 5.5 Drug Evaluation 19
  • All the drugs are evaluated based on mainly two factors: drug risk benefit score and competition intensity 19
    • 5.5.1 Drug Risk Benefit Score 19
    • 5.5.2 Intensity of Competition 20
  • 5.6 Sales Forecasts 20
    • 5.6.1 Target patient Pool of Talactoferrin Alfa 20
    • 5.6.2 Dosing 21
    • 5.6.3 Market Penetration 21
    • 5.6.4 Annual Cost of Therapy 21
    • 5.6.5 Sales Forecasts of Talactoferrin Alfa 22

6 NSCLC Market: Appendix 30

  • 6.1 Market Definitions 30
  • 6.2 Abberiviations 30
  • 6.3 Research Methodology 31
    • 6.3.1 Coverage 31
    • 6.3.2 Secondary Research 31
    • 6.3.3 Forecasting 31
    • 6.3.4 Number of Patients Approved to take the Drug 32
    • 6.3.5 Net Penetration of Drug 32
    • 6.3.6 Net Annual Dosing 33
    • 6.3.7 Annual Cost of Therapy 33
    • 6.3.8 Primary Research 33
    • 6.3.9 Expert Panels 33
  • 6.4 Drug Sales Estimates Model 34
  • 6.5 Contact Us 34
  • 6.6 Disclaimer 34
  • 6.7 Sources 35

1.1 List of Tables

  • Table 1: NSCLC, Incidences and Mortality, 2008-2030 5
  • Table 2: NSCLC, TNM Classification, Primary Tumour (T) 14
  • Table 3: NSCLC, TNM Classification, Regional Lymph Node (N) 14
  • Table 4: NSCLC, TNM Classification, Distant Metastasis (M) 15
  • Table 5: NSCLC, TNM Classification 15
  • Table 6: Drug Risk Benefit Score of Nexavar 19
  • Table 7: Talactoferrin Alfa, NSCLC, Global Sales Forecasts ($m), 2013-2020 22
  • Table 8: Talactoferrin Alfa, NSCLC, The US, Sales Forecasts ($m), 2013-2020 23
  • Table 9: Talactoferrin Alfa, NSCLC, The UK, Sales Forecasts ($m), 2013-2020 24
  • Table 10: Talactoferrin Alfa, NSCLC, France, Sales Forecasts ($m), 2013-2020 25
  • Table 11: Talactoferrin Alfa, NSCLC, Germany, Sales Forecasts ($m), 2013-2020 26
  • Table 12: Talactoferrin Alfa, NSCLC, Italy, Sales Forecasts ($m), 2013-2020 27
  • Table 13: Talactoferrin Alfa, NSCLC, Spain, Sales Forecasts ($m), 2013-2020 28

1.2 List of Figures

  • Figure 1: Percentage Distribution of Top 20 Cancers 4
  • Figure 2: Difference of % Distribution of Incidence and Mortality of Top 20 Cancers 5
  • Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
  • Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 7
  • Figure 6: Total number of cigarettes consumed, The US, 1976-2006 7
  • Figure 4: % Share of Risk Factors in Developed Countries 8
  • Figure 7: NSCLC, Global, Market Size Forecasts ($bn), 2009-2020 10
  • Figure 8: Oncology, Worldwide, Incidence (in million), 2008-2030 11
  • Figure 9: NSCLC, Worldwide, Incidence (in million), 2008-2030 11
  • Figure 10: NSCLC, Worldwide, Mortality (in million), 2008-2030 12
  • Figure 11: Broad Classification of NSCLC 13
  • Figure 12: Classification of NSCLC 16
  • Figure 13: Clinical Studies of Talactoferrin Alfa 18
  • Figure 14: Talactoferrin Alfa, NSCLC, Global Sales Forecasts ($m), 2013-2020 22
  • Figure 15: Talactoferrin Alfa, NSCLC, The US, Sales Forecasts ($m), 2013-2020 23
  • Figure 16: Talactoferrin Alfa, NSCLC, The UK, Sales Forecasts ($m), 2013-2020 24
  • Figure 17: Talactoferrin Alfa, NSCLC, France, Sales Forecasts ($m), 2013-2020 25
  • Figure 18: Talactoferrin Alfa, NSCLC, Germany, Sales Forecasts ($m), 2013-2020 26
  • Figure 19: Talactoferrin Alfa, NSCLC, Italy, Sales Forecasts ($m), 2013-2020 27
  • Figure 20: Talactoferrin Alfa, NSCLC, Spain, Sales Forecasts ($m), 2013-2020 28
  • Figure 21: Talactoferrin Alfa, NSCLC, Global, Sales Distribution (%), 2020 29
  • Figure 22: Drug Model Diagram 32
  • Figure 23: Patients Approved for the Drug 33
Back to Top